Background {#Sec1}
==========

Preoperative chemo(radio)therapy and surgery have been established as the standard treatment for locally advanced esophageal cancer \[[@CR1], [@CR2]\]. Although recent advances in esophagectomy have decreased mortality, the morbidity remains high at 30%-65% \[[@CR3], [@CR4]\]. Among surgical morbidities, infectious complications (ICs) can be lethal if the initiation of effective treatment is delayed. However, the early clinical features of ICs are nonspecific and difficult to distinguish from normal postoperative inflammatory responses associated with surgical invasion \[[@CR5]\]. Therefore, ICs are often diagnosed after patients develop apparent clinical symptoms. Indeed, the median time to the diagnosis ICs was reportedly up to 12 days after surgery \[[@CR6]\]. To improve the short-term outcomes, approaches other than symptom observation must be adopted for the early detection of ICs.

Several studies have reported the utility of serum C-reactive protein (CRP) in predicting ICs before clinical signs and symptoms develop \[[@CR7], [@CR8]\]. However, previous studies have included patients with esophagogastric junctional adenocarcinoma, and some were performed in Western populations. The Eastern surgical procedure, which was defined as radical esophagectomy with extended lymph node dissection, the cervical and upper mediastinal as well as middle-lower mediastinal and abdominal lymph node dissection \[[@CR9], [@CR10]\], for esophageal squamous cell carcinoma located in the thoracic esophagus is a highly invasive surgery, that is completely different from the Ivor-Lewis procedure for esophageal adenocarcinoma located in the distal esophagus \[[@CR11]\]. Furthermore, perioperative managements, such as steroid therapy and enhanced recovery after surgery (ERAS) care, that have been introduced in many hospitals to reduce the morbidity and mortality, were recently reported to reduce the postoperative serum CRP levels \[[@CR12]--[@CR15]\], making ICs more difficult to diagnose in the early period. Thus, the findings from previous reports on the utility of CRP levels in the early prediction of ICs cannot be generalized.

The aim of this study was to assess whether early changes in the serum CRP can be used to predict ICs in advanced esophageal cancer patients who received esophagectomy and two- or three-field lymph node dissection with perioperative steroid therapy and ERAS care.

Methods {#Sec2}
=======

Patient data {#Sec3}
------------

The patients were selected from the medical records of consecutive patients who underwent esophagectomy for esophageal cancer at Kanagawa Cancer Center from January 2011 to September 2015. The patients met the following inclusion criteria: (1) histologically proven primary esophageal squamous cell carcinoma located at thoracic esophagus, (2) clinical stage I to III (excluding T4) disease as evaluated using the 7th edition of the tumor-node-metastasis classification established by the Union for International Cancer Control \[[@CR16]\], and (3) neoadjuvant chemotherapy followed by curative resection with radical lymph node dissection.

Preoperative chemotherapy {#Sec4}
-------------------------

The patients received two courses of cisplatin plus 5-fluorouracil. Cisplatin was administered at a dose of 80 mg/m^2^ by intravenous drip infusion on day 1, and 5-fluorouracil was administered at a dose of 800 mg/m^2^ by continuous infusion on days 1-5 \[[@CR1]\].

Surgical procedure {#Sec5}
------------------

Surgical resection was generally performed 4-6 weeks after the completion of chemotherapy. Our standard procedures consisted of open subtotal esophagectomy via right anterolateral thoracotomy, reconstruction with a gastric tube through the posterior mediastinal route or retrosternal route, and anastomosis in the cervical incision. In principle, two-field lymph node dissection is indicated when tumors are located at the middle thoracic to lower thoracic esophagus, while three-field is applied for upper thoracic tumors. Multiple drains were placed; one to the posterior side of the thoracic cavity and the others on either side of the neck. A feeding tube was routinely placed at the stomach or duodenum.

Perioperative care {#Sec6}
------------------

All of the patients received perioperative management by the clinical path based on the ERAS program, which routinely included antibiotic prophylaxis and steroid therapy. Cefazolin (1 g) was administered 30 min before surgical incision and then again every 3 hours during surgery and at 2 g on postoperative day (POD) 1. Methylprednisolone was administered at a dose of 500 mg on the day of surgery, 250 mg on POD 1, and 125 mg on POD 2 \[[@CR13], [@CR14]\]. Our ERAS program satisfied the 15 items proposed by Fearon et al. \[[@CR17]\]. Briefly, the patients were allowed to eat 30% rice porridge until midnight the day before the surgery and were required to drink the contents of two 500-ml plastic bottles containing oral rehydration solution by 3 h before surgery. Intraoperatively, we conducted epidural anesthesia with morphine for pain control during surgery. Previous study showed the use of the epidural anesthesia with morphine has clinical benefits such as, a selective analgesia with no motor or sympathetic blockade and a long analgesia at low use of rescue medication \[[@CR18], [@CR19]\]. However, the use of the epidural anesthesia with morphine could cause delayed respiratory depression and apnea as late as 12 hours after administration \[[@CR20]\]. Therefore, the patients remained on ventilation for 12 hours after surgery. After 12 hours, we carefully observe respiratory condition and extubate. Ambulation and enteral nutrition was started on POD 1. Oral intake was initiated on POD 6, beginning with water and gelatinous foods. The patients began to eat solid food on POD 9, starting with rice gruel and soft food and progressing in three steps to regular food intake.

Definition of surgical complications and measurement of CRP {#Sec7}
-----------------------------------------------------------

All data were retrospectively retrieved from the patients' records. ICs were defined as complications of anastomotic leakage, pneumonia, abdominal abscess, and/or pyothorax according to the Clavien-Dindo classification \[[@CR21]\] occurring during hospitalization within 30 days after surgery. Of these, ICs ≥ grade IIIa were defined as serious ICs (SICs). The complications were assessed based on the clinical symptoms, blood tests, and X-ray imaging at POD 1, 2, 4, 6, 8, and thereafter. If ICs were suspected, precise examinations, such as computed tomography, esophagography, and esophagoduodenoscopy, were performed.

Statistical analyses {#Sec8}
--------------------

A two-sided *P* value \< 0.05 was considered significant. Continuous data are presented as the median with the range. The Mann-Whitney U test and Fisher\'s exact test were employed to evaluate the differences in continuous and categorical variables, respectively. The patients were classified as those with SICs (SICs group) and those without SICs (NSICs group). The diagnostic accuracy was determined based on the area under the receiver operating characteristic (ROC) curve (AUC) \[[@CR22]\]. The optimal cut-off value of CRP was determined by maximizing Youden's index. The optimum value of CRP was then determined based on the AUC and the earliest prediction of SICs. The predictive value of CRP, categorized as high or low by the cut-off value at the optimum point, was examined using univariate and multivariate logistic regression analyses. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Australia). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics \[[@CR23]\].

Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

A total of 208 patients underwent esophagectomy for esophageal squamous cell carcinoma between January 2011 and September 2015. Excluding 3 patients with no survival information available, 7 patients who were not diagnosed with squamous cell carcinoma, 74 patients who did not receive neoadjuvant chemotherapy, and 7 patients who did not receive curative resection, one hundred and seventeen of these patients were eligible for the present study (56.3%). The patient characteristics are summarized in Table [1](#Tab1){ref-type="table"}. The SICs group received three-field lymph node dissection more frequently (*p* = 0.023) and had greater blood loss (*p* = 0.018) than the NSICs group.Table 1A comparison of patients' characteristics and surgical findings between the patients with and without postoperative serious infectious complicationsVariablesAll Patients\
(*n* = 117)SICs group\
(*n* = 20)NSICs group\
(*n* = 97)*p* valueAge (years), median (range)66 (48-77)68 (50-77)66 (48-77)0.289Gender0.356 Male94 (80.3%)18 (90.0%)76 (78.4%) Female23 (19.7%)2 (10.0%)21 (21.6%)Preoperative body mass index (kg/m2), median (range)21.1 (15.4-28.9)21.8 (17.8-26.7)20.5 (15.4-28.9)0.205Preoperative serum albumin (g/dl), median (range)4.1 (2.3-6.4)4.1 (3.2-4.4)4.1 (2.3-6.4)0.202ASA-PS0.779 117 (14.5%)2 (10.0%)15 (15.5%) 299 (84.6%)18 (90.0%)81 (83.5%) 31 (0.9%)0 (0.0%)1 (1.0%)Main tumor location0.091 Upper thoracic esophagus16 (13.7%)6 (30.0%)10 (10.3%) Middle thoracic esophagus61 (52.1%)9 (45.0%)52 (53.6%) Lower thoracic esophagus40 (34.2%)5 (25.0%)35 (36.1%)UICC clinical T factor before neoadjuvant chemotherapy0.235 cT12 (1.7%)1 (5.0%)1 (1.0%) cT239 (33.3%)8 (40.0%)31 (32.0%) cT376 (65.0%)11 (55.0%)65 (67.0%)UICC clinical N factor before neoadjuvant chemotherapy0.841 cN050 (42.7%)8 (40.0%)42 (43.3%) cN166 (56.4%)12 (60.0%)54 (55.7%) cN21 (0.9%)0 (0.0%)1 (1.0%)UICC clinical stage before neoadjuvant chemotherapy0.090 IB23 (19.7%)7 (35.0%)16 (16.5%) IIA27 (23.1%)1 (5.0%)26 (26.8%) IIB18 (15.4%)2 (10.0%)16 (16.5%) IIIA48 (41.0%)10 (50.0%)38 (39.2%) IIIB1 (0.9%)0 (0.0%)1 (1.0%)Lymph node dissection0.023 Two-field95 (81.2%)12 (60.0%)83 (85.6%) Three-field22 (18.8%)8 (40.0%)14 (14.4%)Operation time (min), median (range)400 (298-593)430.0 (345-593)395\
(298-593)0.111Intraoperative blood loss (ml), median (range)420 (110-3000)682.5 (185-3000)400 (110-2350)0.018*SICs* Serious infectious complications, *ASA-PS* American Society of Anesthesiologists Physical Status, *UICC* Union for International Cancer Control

Surgical morbidity and mortality {#Sec11}
--------------------------------

SICs were observed in 20 patients (17.1%). The details of the complications and duration from surgery to their diagnosis are shown in Table [2](#Tab2){ref-type="table"}. The median duration until the diagnosis of any SICs was 7 days (range: 4-14).Table 2Details of serious infectious complications and duration from surgery to the diagnosis of those complicationsGrade according to Clavein-Dindo classificationTotal (%)Duration to diagnose SICs, median (range)Complications3a3b4a4b5Anastomotic leakage16000016 (13.7%)6 (4-10)Abdominal abscess010001 (0.9%)7 (7)Pneumonia101002 (1.7%)6 (5-7)Pyothorax500005 (4.3%)10 (6-14)Total22110024 (20.5%)7 (4-14)There is some overlapping.*SICs* Serious infectious complications, *POD* Postoperative day

Postoperative CRP level with SICs {#Sec12}
---------------------------------

The changes in the CRP level after esophagectomy are shown in Fig. [1](#Fig1){ref-type="fig"}. The preoperative CRP level was not markedly different between the SICs and NSICs groups. After surgery, the CRP level reached its first peak on POD 1 and 2, with no significant differences between the two groups, and then decreased to its lowest value on POD 4. However, the subsequent CRP levels on POD 4, 6, and 8 were significantly higher in the SICs group than in the NSICs group. The AUC for prediction by CRP was 0.778 (95% CI, 0.673-0.884) on POD 4 (Fig. [2a](#Fig2){ref-type="fig"}), 0.875 (95% CI, 0.799-0.952) on POD 6 (Fig. [2b](#Fig2){ref-type="fig"}), and 0.883 (95% CI, 0.813-0.953) on POD 8 (Fig. [2c](#Fig2){ref-type="fig"}). Considering the AUC and earliest prediction of SICs, the optimum cut-off value of CRP was determined to be 4.0 mg/dl on POD 4. By this cut-off, 40 patients had high CRP with median of 6.95 mg/dl (range: 4.01-28.51), while 77 patients had CRP with median of 1.50 mg/dl (range: 0.13-3.99). Among 40 patients with high CRP levels, 16 developed SICs; anastomotic leakage in 12 patients, pneumonia in 2, abdominal abscess in 1, and pyothorax in 3. The sensitivity and specificity were 80.0% and 75.3%, respectively, and the negative and positive predictive values (NPV and PPV) were 94.8% and 40.1%, respectively.Fig. 1Changes in the C-reactive protein (CRP) levels between patients with and without serious infectious complications (SICs). The CRP levels were significantly different on postoperative days 4, 6, and 8. The optimum CRP value for the prediction of SICs was determined to be that measured on POD 4 Fig. 2Diagnostic accuracy was determined based on the area under the receiver operating characteristic (ROC) curve (AUC) (CRP on POD 4, 6, and 8) for predicting SICs. The AUC for prediction by CRP was 0.778 (95% CI, 0.673-0.884) on POD 4 (**a**), 0.875 (95% CI, 0.799-0.952) on POD 6 (**b**), and 0.883 (95% CI, 0.813-0.953) on POD 8 (**c**)

Risk factors for SICs {#Sec13}
---------------------

Table [3](#Tab3){ref-type="table"} shows the results of univariate and multivariate analyses (Table [3](#Tab3){ref-type="table"} **)**. Among these, CRP ≥ 4.0 mg/dl on POD 4 (odds ratio, 18.600; 95% CI, 4.610--75.200) and three-field lymph node dissection (odds ratio, 7.950; 95% CI, 1.900--33.400) were identified as significant independent predictive factors for SICs.Table 3Predictive factors for serious infectious complicationsFactorsNumber of patients (%)UnivariateMultivariateOR95% CI*p* valueOR95% CI*p* valueAge (years)0.271 ≤6660 (51.3%)1.000  \>6657 (48.7%)1.7300.651-4.620Gender0.246 Female23 (19.7%)1.000 Male94 (80.3%)2.4900.534-11.600Preoperative body mass index (kg/m2)0.183 ≤2157 (48.7%)1.000  \>2160 (51.3%)1.9800.726-5.380ASA-PS0.531 117 (14.5%)1.000 2/3100 (85.5%)1.6500.346-7.840Preoperative serum albumin (g/dl)0.900 ≥4.160 (51.3%)1.000 \<4.157 (48.7%)1.0600.406-2.790UICC clinical T factor before neoadjuvant chemotherapy0.308 cT1-241 (35.0%)1.000 cT376 (65.0%)0.6020.226-1.600UICC clinical N factor before neoadjuvant chemotherapy0.786 cN050 (42.7%)1.000 cN1-267 (57.3%)1.1500.430-3.050Lymph node dissection0.0110.005 Two-field95 (81.2%)1.0001.000 Three-field22 (18.8%)3.9501.370-11.4007.9501.900-33.400Operation time (min)0.135 ≤40059 (50.4%)1.000 \>40058 (49.6%)2.1500.788-5.840Intraoperative blood loss (ml)0.237 ≤42061 (52.1%)1.000 \>42056 (47.9%)1.8100.678-4.810CRP on POD4 (mg/dl)\<0.001\<0.001 ≤4.077 (65.8%)1.0001.000 \>4.040 (34.5%)12.2003.710-39.90018.6004.610-75.200*SICs* Serious infectious complications, *CI* Confidence interval, *OR* odds ratio, *ASA-PS* American Society of Anesthesiologists Physical Status, *CRP* C-reactive protein; *POD*, postoperative day, *UICC* Union for International Cancer Control

Discussion {#Sec14}
==========

The present study examined whether CRP levels can predict SICs in 117 advanced esophageal squamous cell carcinoma patients who received neoadjuvant chemotherapy followed by curative resection with perioperative steroid therapy and ERAS care. This study found that a CRP level exceeding 4.0 mg/dl on POD 4 was useful for predicting SICs in esophageal squamous cell carcinoma patients who received radical esophagectomy with perioperative steroid therapy and ERAS care. A high CRP level on POD 4 may encourage the performance of imaging studies to detect the focus and thereby lead to early medical and/or surgical intervention.

The cut-off CRP value was 4.0 mg/dl on POD 4 in the present study. Compared with previous studies examining the utility of CRP in predicting SICs, our surgical approach was highly invasive, but the operation time and blood loss were similar \[[@CR24], [@CR25]\]. However, the cut-off CRP value was much lower than in previous studies, ranging from 11.1 to 18.0 mg/dl on POD 3 or 4 \[[@CR7], [@CR8], [@CR26]\]. This low cut-off CRP value may be explained by the use of steroid therapy and ERAS in our study, which helped reduce the surgical stress-induced inflammatory responses \[[@CR12]--[@CR15]\]. Several studies reported that the postoperative CRP levels were decreased to nearly half in patients who underwent esophagectomy and received perioperative steroid therapy \[[@CR13], [@CR14]\]. Furthermore, Chen et al. found that the postoperative CRP levels on POD 1, 3, and 7 were significantly lower in patients who received perioperative care with fast track surgery than in others \[[@CR15]\].

Although the cut-off CRP value in the present study was low, the sensitivity and specificity were around 70%-80%, which was concordant with the values in previous studies \[[@CR7], [@CR8], [@CR26], [@CR27]\]. Furthermore, the high NPV of 94.8% in the present study suggested that SICs can be ruled out when the CRP is less than 4.0 mg/dl on POD 4 \[[@CR28]\]. However, the PPV of 40.1% might be too low to support the accurate diagnosis of SICs based on CRP values. Therefore, patients with CRP levels ≥ 4.0 mg/dl on POD 4 must be screened for SICs by further diagnostic measures, like X-rays, upper gastrointestinal series, or computed tomography. CRP measurement on POD 4 is nonspecific, but it is nevertheless helpful since it encourages the performance of further studies to detect the focus \[[@CR27]\].

The earliest point for the successful prediction by the CRP level was POD 4 in the present study, which has clinical impact as physicians can initiate early goal-directed therapy, thereby improving patients' short-term outcome \[[@CR5], [@CR24]\]. Generally, the half-life of CRP is 19 h \[[@CR29]\]. Several investigators have reported that the CRP level peaked on POD 2 before normalizing on POD 3 following various types of surgery \[[@CR7], [@CR28], [@CR29]\]. Because this study did not measure the CRP level on POD 3, it remains unclear whether SICs could be predicted on POD 3. However, the CRP level on POD 6 and 8 had high diagnostic accuracy in the present study, possibly suggesting that CRP increased with the progression of SICs; however, no effective treatment was introduced, possibly due to the lack of any clinical sign of SICs. In other words, SICs may actually start on POD 4 rather than simply being detected on that day. This hypothesis is supported by the findings from previous studies \[[@CR27], [@CR30]\], as Deitmar et al. showed that elevated CRP levels precede the development of SICs by 3 days \[[@CR30]\].

Our results demonstrated that three-field lymph node dissection had more complications than two-field. According to the previous reports, it is controversial whether the addition of lateral neck dissection may lead to SICs \[[@CR9]\]. Recent meta-analysis showed that three-field lymph node dissection had more complications than two-field \[[@CR31]\]. In this study, three-field lymph node dissection was applied for upper thoracic tumors, which might have resulted in SICs. Although the difference between two- or three-field lymph node dissection is just whether lateral neck dissection is added or not, technical difficulties in surgery for the proximal esophagus might increase SICs \[[@CR32]\]. In fact, postoperative complications had been reported in as high as 61.5 to 71.4% of patients with the upper thoracic esophageal cancer \[[@CR33]\].

The present study is associated with several potential limitations. First, it was a retrospective single-center study with a small sample size. Second, there is no standard type, period, or dose of perioperative steroid therapy. The perioperative ERAS program also differs by hospital. Thus, the cut-off CRP value likely differs depending on the perioperative management regimen adopted by a given hospital. Third, the present study only investigated the outcomes following open subtotal esophagectomy via right anterolateral thoracotomy. Recently, minimally invasive surgery has been introduced \[[@CR34]\]. Because the invasiveness of surgery is different, the cut-off CRP value may also be different with minimally invasive surgery. To confirm the present results, prospective study is necessary.

Conclusions {#Sec15}
===========

A high CRP level ≥ 4.0 mg/dl on POD 4 may predict SICs in esophageal cancer patients who received neoadjuvant chemotherapy followed by curative resection with perioperative steroid therapy and ERAS care. This result may encourage the performance of imaging studies to detect the focus and thus lead to early medical and/or surgical intervention, thereby helping to improve the short-term outcome.
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